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Abstract (193 words) 
 
IgG monoclonal antibodies have made significant contributions to cancer therapy, 
but suffer from several limitations that restrict their effectiveness in unleashing host 
immune system components against tumors. The development of monoclonal 
antibodies of an alternative class, namely IgE, may offer enhanced immune 
surveillance and superior effector cell potency against cancer cells. In our recent 
manuscript, we elaborate our proof-of-concept studies of a mouse/human chimeric 
IgE antibody (hMOv18 IgE), which is specific for the cancer-associated antigen folate 
receptor alpha (FRα). We demonstrate superior anti-tumor efficacy for IgE compared 
with an otherwise identical IgG in a syngeneic immunocompetent animal, and we 
identify TNFα/MCP-1 signaling as an IgE-mediated mechanism of monocyte and 
macrophage activation and recruitment to tumors. These findings draw parallels 
with powerful macrophage-activating functions employed by IgE against parasites, 
rather than allergic IgE mechanisms. The potential clinical application of IgE-derived 
drugs in clinical oncology is clear if the anti-tumor activity of MOv18 IgE in these 
preclinical experiments can be replicated in patients. In particular, different IgE 
antibodies with specificity for many other antigens already validated as targets for 
IgG suggest a wide potential for development of a novel class of antibody therapy.  
 
 
Text word count: 2,493  
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Antibodies in cancer therapy and their limitations 
Immunotherapy has become one of the most dynamic and rapidly-expanding areas 
of cancer therapy in recent years. One arm of the immunotherapeutic 
armamentarium, namely monoclonal antibodies, has been used with considerable 
success over the past 20 years, and now constitutes a vital component of 
contemporary cancer therapy (1). Monoclonal antibodies in current clinical use 
variously induce their therapeutic effects either through molecular signal blockade 
(for example by competitive inhibition of ligand binding to a transmembrane 
receptor), or by recruiting effector cells expressing the Fc-gamma receptor family 
members. Despite impressive results, however, antibody-based treatments continue 
to face limitations. Adequate binding of antibody to tumor antigens depends upon 
favorable pharmacokinetics, and efficient penetration and retention of the molecule 
in the targeted tissue. These binding properties are determined by antibody size, 
shape, receptor affinity and valency. All currently approved antibodies are members 
of the IgG class, characterized by their large molecular size, very long serum half-life 
of up to 3 weeks, and poor tissue retention. As a result of these biological properties, 
IgG molecules do not provide very efficient surveillance of the tissue compartment, 
which may limit the overall efficacy of existing therapeutic antibodies.  
Once bound to cell surface antigens, therapeutic antibodies have the potential to 
elicit immune-mediated tumor cell death, either by engaging cell lineages of the 
innate immune system, or by activating the complement cascade. Antibody-
dependent cell mediated cytotoxicity and phagocytosis (ADCC and ADCP) are 
dependent on interactions between Fc receptors (FcRs) expressed on the surface of 
immune cells, and the antibody Fc domain. Indeed, Fc-mediated mechanisms of 
immune system engagement appear to play an important role in the anti-tumor 
efficacy of the majority of approved antibodies for cancer therapy today. However, 
the triggering of Fc-mediated immune effector cell engagement by therapeutic IgGs 
may be limited by several factors, including i) the low affinity of IgG for its FcγRs, 
(requiring the formation of immune complexes to achieve adequate retention and Fc 
signaling of antibodies by effector cells), ii) glycosylation of antibody Fc regions 
(known to reduce FcγR affinity), iii) competition with native IgGs (especially IgG4) for 
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binding to FcγRs, and iv) inhibitory Fc receptors such as FcγRIIb expressed on B cells, 
macrophages, dendritic cells and neutrophils (2). 
 
Macrophages in the tumor microenvironment 
Cancer cells rely on resident and recruited ‘accessory cells’ to support their 
proliferation. Such cells include those forming the vasculature and lymphatics, 
tissue-specific mesenchymal support cells, and myeloid and lymphoid-lineage 
immune cells. Interactions between neoplastic cells and cellular components of the 
tumor microenvironment (TME) have prompted research into immunotherapeutic 
approaches aimed at neutralizing tumor-promoting chronic inflammation, or at 
releasing the cytotoxic activities of antigen-specific T cells (3).  
Although the development of monoclonal antibody therapies has traditionally 
focused on targeting the tumor cell itself, more recently attention has shifted 
towards targeting the TME and its cellular components. Clinical application of IgG 
antibodies blocking inhibitory components of the immune checkpoint, in particular T 
cell signaling mediated by CTLA4 and PD-1, has been the most successful application 
of this new strategy to date (4). Reactivation or reprogramming of cells within the 
TME may provide the key to further success with antibody-mediated cancer 
immunotherapy.  
Macrophages are a prominent component of the cellular TME, where they exert a 
profound influence over the tumor immunologic composition (5). Macrophages are 
phenotypically diverse members of the mononuclear phagocyte family, distributed 
throughout every organ of the body. Previously thought to be derived exclusively 
from circulating monocytes, tissue-resident macrophages have more recently been 
found to be established in utero, and to be able to replenish their numbers 
independently of circulating monocytes (6). These tissue-resident macrophages are 
maintained locally via colony stimulating factor 1 (CSF1), a key growth factor 
produced by the local tissue stroma (6, 7) and may also be enhanced by recruitment 
and differentiation of circulating monocytes (7). Tumor-associated macrophages 
(TAMs) are recruited into tumors following activation of their CSF1 receptor (CSF1R) 
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by either CSF1 or IL-34. In addition, the chemokine CCL2/MCP-1 may facilitate 
macrophage recruitment into tumors (8).  
Under physiological conditions, macrophages act as phagocytes, serving as an early 
line of defense against pathogens. They are specialized to engulf and digest cellular 
debris and drive adaptive immune responses. Despite a common progenitor, TAM 
populations are functionally diverse, ranging from anti-tumor, pro-inflammatory 
(M1) macrophages to tumor-promoting, anti-inflammatory (M2) populations (5). 
Macrophages are therefore implicated both as essential mediators in anti-tumor 
immune responses as well as drivers of local tolerance and even tumor-promoting 
inflammation. Indeed, within the TME, innumerable tumor- and stromal-derived 
factors may suppress the tumoricidal activity of TAMs, endowing them with 
properties characteristic of M2 macrophages, so facilitating tumor growth, 
metastasis and immune evasion. In this way, TAM infiltration may correlate with 
poor prognosis and disease outcome in many human cancers (9). By contrast, dense 
tumor infiltration by macrophages in lymphoma patients is associated with improved 
outcome following a rituximab-containing regimen, in contrast to inferior survival in 
the absence of rituximab treatment (10). This suggests that tumor macrophage 
infiltration may be a favorable factor specifically in the context of treatment with 
monoclonal antibodies. 
 
Enhancing the efficacy of antibody therapy: harnessing the effector functions of IgE 
antibodies 
Efforts to boost the efficacy of anti-tumor IgGs have involved modification of the IgG 
constant (Fc) region to strengthen its ability to interact with the human immune 
system. Approaches to enhance this interaction include altering Fc region amino acid 
sequences (11) or changing the glycosylation pattern of the Fc region to enhance 
interaction with FcγRs on effector cells (12). Another strategy to optimize the 
antibody-immune system interaction has been exploration of antibodies with Fc 
regions of alternative immunoglobulin classes, such as IgE. Work in this area 
constitutes an important branch of the rapidly-growing field of AllergoOncology, 
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which aims to address the potential opportunities of IgE-mediated and Th2-biased 
cellular responses in malignant diseases (13, 14). The key hypothesis underlying IgE 
immunotherapy is that this antibody class can recruit a different effector cell 
population, utilizing the cognate FcεRs expressed on those cells. Innate immune cells 
such as macrophages may be reactivated and retargeted by anti-tumor IgE to 
overcome inhibitory effects of the TME. 
Beside its critical role in allergy, IgE plays a physiological role in immunity against 
parasitic infections, by a number of different mechanisms and via a number of IgE 
receptor-expressing cell types including monocytes and macrophages (15). The 
particular properties that make IgE a key contributor to the allergic response, and 
permit protection against parasitic infections, suggest the potential value of 
antibodies in this class as therapeutic agents in cancer. The manifestations of local 
immune stimulation seen in parasitic infestation, with an ensuing cascade of effector 
cell activation and inflammation at the site of antigen provocation, might be 
harnessed by IgE therapies to induce tumor rejection. Macrophages are likely to be a 
key cell population implicated in such an IgE-mediated anti-cancer effect, because 
they are known to be pivotal effectors in the control of intracellular and extracellular 
parasites by IgE through engendering effector mechanisms such as ADCC and ADCP 
(16, 17).  
The potential biological advantages of IgE antibodies outlined above, and the 
presence in solid tumors of many key FcεR-expressing immune effector cells 
including macrophages, provide a rationale for the development of tumor-specific 
therapeutic IgE molecules (13, 14). Work by Josephs et al. describes proof-of-
concept studies building upon our previous studies of a mouse/human chimeric IgE 
antibody (MOv18 IgE) specific for the ovarian cancer-associated antigen folate 
receptor alpha (FRα) (13, 18-20). Here, in an immunocompetent rodent model of 
pulmonary metastases from a syngeneic tumor expressing human FRα, we 
demonstrated clear superiority of anti-tumor activity for IgE compared to IgG, in line 
with our previous findings in two in vivo models of cancer with reconstituted human 
cellular immunity (21). 
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A role for human monocytes was previously demonstrated in vitro via both ADCC 
(mediated by the IgE high affinity receptor FcεRI, expressed by a proportion of 
monocytes/macrophages), and ADCP (through CD23, the low affinity IgE receptor, 
expressed on the surface of IL-4-activated monocytes/macrophages). ADCC and 
ADCP are both known mechanisms of action for IgE in the defense against parasitic 
infections. This provided a rationale in favor of further exploring the IgE-mediated 
anti-tumor functions of these cells (19, 20). In a nude mouse xenograft model of 
FRα-positive patient-derived ovarian carcinoma with cellular immunity reconstituted 
using human peripheral blood mononuclear cells (PBMCs), control of tumor growth 
using chimeric mouse/human MOv18 IgE (hMOv18 IgE) was superior to that of the 
IgG1 anti-FRα counterpart. Tumor xenografts were infiltrated by human monocytes 
in hMOv18 IgE-treated mice. Use of monocyte-depleted PBMCs in this model 
resulted in a loss of the survival advantage conferred by hMOv18 IgE (20). This 
indicated that monocytes may play an important role in the anti-tumor effect of 
hMOv18 IgE in vivo (20). 
Based on these findings, we sought to explore the role of the monocyte/macrophage 
lineage in mediating tumor cell killing by IgE in an immunocompetent model. We 
further hypothesized that IgE may recruit and re-educate these cells to adopt an 
activated phenotype.  
 
IgE-mediated macrophage recruitment and activation  
In the study recently reported in Cancer Research we sought to ascertain how anti-
tumor IgE antibodies may be applied to recruit macrophages and to reprogram these 
cells to eradicate cancer cells (21). Our work reveals a previously-unappreciated 
contribution of a TNFα/MCP-1 cascade to monocyte and macrophage re-education 
and recruitment in an immunocompetent rat tumor model, specifically chosen for its 
suitability to examine IgE effector functions (Fig. 1).  
MOv18 IgE inhibited tumor growth and induced pronounced infiltration of CD68-
positive monocytes/macrophages deep into rat tumors. In concordance, the degree 
of intra-tumor macrophage influx significantly correlated with prolonged survival of 
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IgE-treated mice bearing patient-derived tumor xenografts. There is evidence to 
suggest that the location of TAMs in relation to tumor cells in human cancer can 
influence clinical outcome (22). Macrophage density within tumor islets was 
positively associated with survival of patients with lung cancer, whereas a 
concentration of these cells in the stroma, away from tumor cells, was negatively 
prognostic. Furthermore, the ratio of macrophage density in the tumor islets to 
macrophage density in the tumor stroma appeared to correlate better with survival 
(22). Therefore, effective MOv18 IgE-induced tumor infiltration by macrophages may 
represent a mechanistic explanation for the observed superior anti-cancer activity 
compared with IgG.  
In the MOv18 IgE-treated immunocompetent model, the phenotype of tumor lung 
metastases-infiltrating macrophages is different to that of macrophages from the 
MOv18 IgG or buffer control groups: tumor-associated macrophages from MOv18 
IgE-treated rats featured elevated surface expression of the macrophage maturation 
and co-stimulatory marker CD80, higher intracellular expression of the pro-
inflammatory and cytotoxic mediator TNFα, and some elevation of IL-10. TNFα was 
also found to be a prominent cytokine within the airways of MOv18 IgE-treated rats 
(broncho-alveolar lavage – BAL), alongside the macrophage chemoattractant MCP-1 
and IL-10. This points to the presence of a distinct macrophage compartment, and a 
specific immune mediator signature in tumor environments, both associated with 
IgE therapy. 
In our study, we have shown that cross-linking of IgE, but not IgG, of any antigen 
specificity bound to monocytes triggers upregulation of TNFα expression (Fig. 1A). 
This is likely to be a function of the high affinity of IgE for FcεRI on macrophages, and 
may be facilitated by molecular patterns displayed by tumor antigens (designated 
Tumor-Associated Molecular Patterns; TAMPs) (23). TAMPs can promote crosslinking 
of IgE bound to FcεRs on effector cells, thereby fostering more sustained interactions 
of macrophages with IgE than with IgG, and leading in turn to higher levels of TNFα 
in the tumor microenvironment. MOv18 IgE-mediated tumor ADCC was abrogated in 
vitro by TNFα receptor-specific blockade of monocyte effector cell functions, 
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pointing to the contribution of TNFα signaling in anti-tumor IgE effector functions 
(21).  
In addition to TNFα, the other key analyte elevated in the BAL fluid from rats treated 
with MOv18 IgE was MCP-1, a member of the CC family of chemokines, a potent 
chemo-attractant for macrophages and a macrophage-related pro-inflammatory 
chemokine (24). We demonstrate that upregulation of TNFα by monocytes could 
promote enhanced MCP-1 expression by both monocytes and importantly by tumor 
cells (Fig. 1B). This IgE-specific macrophage activation and recruitment mechanism 
seems to be generalizable, since TNFα triggered higher MCP-1 production by a 
number of different tumor cell types.  
Studies have suggested that MCP-1 produced by tumor cells may be responsible for 
chemotaxis of monocytes, mast cells and CD8+ T-cells into the TME (25). The 
markedly increased recruitment of macrophages deep into tumors observed in 
animals treated with MOv18 IgE, compared to MOv18 IgG, may therefore result 
from the MCP-1 upregulation described above (Fig. 1C).  
Taken together, our findings are consistent with a positive feedback interaction 
engendered by IgE-, but not IgG-, Fc engagement and cross-linking on the surface of 
macrophages. Initial tumor cell–macrophage interactions fostered by tumor antigen-
specific IgE may trigger a TNFα-mediated MCP-1 upregulation cascade that may 
further mobilize macrophages or recruit additional macrophages into tumors. 
 
Re-programing macrophages towards a tumoricidal function  
The plasticity of tumor-associated macrophages may be exploited therapeutically in 
order to restore their anti-tumor properties. Strategies to re-program Th2-driven 
myeloid cells to reduce the immunosuppressive status of macrophages, trigger anti-
tumor immunity, or suppress tumor growth have all been pursued in several tissue-
specific cancer models (26-30) (Fig. 1D). For instance, CSF1-neutralizing monoclonal 
antibodies and small-molecule CSF1R inhibitors have been evaluated, as 
monotherapy or in combination with chemotherapy, radiotherapy or other 
immunotherapies, for their ability to suppress macrophage survival and/or presence 
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in tumors (26, 31). TAMs have also been therapeutically manipulated by inhibiting 
the macrophage transmembrane receptor kinase RON (27). Other strategies include 
antibody-mediated activation of co-stimulatory CD40 or blocking of inhibitory IL-10, 
delivery of immunostimulatory cytokines such as IL-12, or the administration of Toll-
like receptor (TLR) agonists including imiquimod (28-30). It may be that IgE therapies 
could join these other novel approaches in targeting pro-tumorigenic immune cells 
including macrophages, so altering the TME in a way that fosters their cytotoxic 
properties.  
Although pivotal in the control of parasites via IgE, physiological macrophage activity 
appears to be suppressed in tumors. Our findings point to the possibility that 
administration of therapeutic IgE antibodies may re-direct macrophage functions, 
evolved to neutralize parasites, against cancer cells. TNFα, MCP-1, nitric oxide (NO) 
and IL-10 are all upregulated during parasiticidal activities of macrophages (17). 
Upregulation of TNFα and MCP-1 is detected in tumors in response to IgE therapy, 
but the classical Th2 cytokine IL-4 is notably absent. This indicates that parasite-
targeting rather than allergic, mechanisms are dominant in this context. 
Furthermore, analysis of publically-available ovarian gene expression libraries 
suggests a positive prognostic role for elevated TNFα/MCP-1 levels, as well as for 
macrophage and FcεR markers, highlighting the clinical significance of this mediator 
signature in patients with cancer (21).  
In the future it is possible that the clinical use of IgE class antibodies to combine 
engagement, recruitment and activation of tumor-associated macrophages could 
ignite the tumoricidal properties of these cells, and open new and compelling 
therapeutic opportunities. Improved understanding of relevant activating cytokine 
cascades, normally associated with parasite clearance, could further harness this 
hitherto unappreciated mechanism of human immune defense against cancer.  
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Figure Legend 
Fig 1. Effects of anti-cancer strategies including anti-tumor IgE antibodies 
on macrophages. Activation of macrophages by anti-tumor IgE-mediates a 
TNFα/MCP-1 axis (A-B) and promotes potent recruitment of macrophages (C). (A) IgE 
engagement with Fcε receptors on the surface of macrophages is not sufficient for 
effector cell activation (i). Cross-linking of tumor-targeting IgE antibodies on 
macrophages by polyclonal anti-IgE (ii) or antigen-bearing tumor cells (iii) is 
necessary for upregulation of TNFα by macrophages. (B) TNFα then stimulates 
production of MCP-1 by macrophages and tumor cells, which promotes potent 
chemotaxis of further macrophages into tumors resulting in enhanced tumor cell-
macrophage interactions and subsequent tumor cell death (C). Anti-tumor 
mechanisms of established and novel anti-cancer therapies on macrophages include: 
reprogramming to a new macrophage phenotype, macrophage recruitment, 
repolarization to an M1-like phenotype, activation to trigger antibody-mediated 
tumor cell death (e.g. by ADCC, ADCP, immunoactivatory cytokines), and suppression 
of immunosuppressive tumor-associated macrophage survival (D).  
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